Beck Bode LLC’s bluebird bio BLUE Stock Holding History

Beck Bode LLC’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12	Closed	-$5K	–	109
2021 Q2	$5K	Buy	+12	New	+$4.75K	﹤0.01%	262

Other funds holding BLUE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Beck Bode LLC's BLUE Position: Q3 2021 in Review

Beck Bode LLC sold out of bluebird bio (BLUE) in Q3 2021, closing a stake of 12 shares — an estimated $5K sold.

Beck Bode LLC first reported a position in BLUE in Q2 2021 and held it in 1 quarter. The position peaked at $5K in Q2 2021. 196 funds tracked by Wall St. Rank hold BLUE as of Q3 2021.

Beck Bode LLC reported no remaining bluebird bio position as of Q3 2021 after selling out during the quarter.
Beck Bode LLC sold 12 bluebird bio shares in Q3 2021, an estimated $5K.
Beck Bode LLC first reported a position in bluebird bio in Q2 2021 and held it in 1 quarter.
Beck Bode LLC's bluebird bio position peaked at $5K in Q2 2021.
196 funds tracked by Wall St. Rank held bluebird bio as of Q3 2021.

Based on Beck Bode LLC's 13F filing for Q3 2021, filed 22 Oct 2021.